Stock Screener App

무료 -

29.65

1.33% -0.44

BridgeBio Pharma Inc (BBIO)

개요 뉴스 가격 이력 옵션 체인 Financials BBIO 왜 하락? 토론 예측

BridgeBio Pharma Inc 주식(BBIO)의 최신 뉴스

Charles Schwab Investment Management Inc. Acquires 66,945 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

(BBIO) Investment Report - Stock Traders Daily

Stock Traders Daily

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Position Lifted by Charles Schwab Investment Management Inc. - Defense World

Amalgamated Bank Reduces Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

Principal Financial Group Inc. Purchases 197,818 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Evercore ISI Upgrades BridgeBio Pharma (NASDAQ:BBIO) to Strong-Buy - MarketBeat

BridgeBio Pharma's Options: A Look at What the Big Money is Thinking - BridgeBio Pharma (NASDAQ:BBIO) - Benzinga

BridgeBio Pharma (NASDAQ:BBIO) Raised to Strong-Buy at Evercore ISI - Defense World

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Sees Large Increase in Short Interest - MarketBeat

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 7.7% in April - Defense World

BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo News UK

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Canada Finance

Yahoo Canada Finance

BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated by Analysts at Evercore ISI - Defense World

BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Evercore ISI - MarketBeat

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 - GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 - Yahoo Finance

BridgeBio Pharma shares get Outperform rating on positive outlook - Investing.com Canada

Investing.com Canada

BridgeBio's Acoramidis shows promise in heart disease study - Investing.com Canada

Investing.com Canada

BridgeBio Pharma shares get Outperform rating on positive outlook By Investing.com - Investing.com UK

Investing.com UK

BridgeBio's Acoramidis shows promise in heart disease study - Investing.com

BridgeBio's Acoramidis shows promise in heart disease study By Investing.com - Investing.com UK

Investing.com UK

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin ... - Yahoo Finance

Atria Wealth Solutions Inc. Acquires Shares of 5313 BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

Pre-Market Movers: Godaddy Pops, Didi, Airlines, and BridgeBio Pharma Sell Off - Yahoo Singapore News

Yahoo Singapore News

Victory Capital Management Inc. Boosts Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment - MSN

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Zacks Investment Research

Where are the Opportunities in (BBIO) - Stock Traders Daily

Stock Traders Daily

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year? - Yahoo News Australia

Yahoo News Australia

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

Zacks Investment Research

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

BridgeBio Oncology Therapeutics Completes $200 Million Private Financing | News & Events | Goodwin - Goodwin Procter

Goodwin Procter

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year? - Yahoo Lifestyle UK

Yahoo Lifestyle UK

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Canada Shine On

Yahoo Canada Shine On

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today - Yahoo Finance

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Sees Significant Growth in Short Interest - Defense World

Venture report: Rounds for psychedelic play Reunion, cancer company Delphia - BioCentury

BridgeBio Pharma spins out cancer-focused unit with three drugs, $200 million - The Business Journals

The Business Journals

BridgeBio spinout launches with $200M for KRAS cancer drugs - Yahoo Finance

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Sees Large Increase in Short Interest - MarketBeat

Jennison Associates LLC Has $781000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance Australia

Yahoo Finance Australia

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

GlobeNewswire Inc.

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical ... - Yahoo Finance

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Zacks Investment Research

BridgeBio Pharma: Assessing Acoramidis' Market Opportunity (NASDAQ:BBIO) - Seeking Alpha

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Latham & Watkins Advises on BridgeBio's Public Offering of Common Stock - Latham & Watkins LLP -

Latham & Watkins LLP -

$150.29

0.60%

$76.45

1.45%

$29.80

0.53%

$173.87

0.63%

$365.32

0.14%

$92.39

1.95%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기